FWM
KERX

Focused Wealth Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Focused Wealth Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-500
Closed -$5K – 740
2015
Q2 		$5K Hold
500
– – ﹤0.01% 516
2015
Q1 		$6K Hold
500
– – ﹤0.01% 515
2014
Q4 		$7K Hold
500
– – 0.01% 478
2014
Q3 		$7K Hold
500
– – 0.01% 482
2014
Q2 		$8K Hold
500
– – 0.01% 462
2014
Q1 		$9K Hold
500
– – 0.01% 420
2013
Q4 		$6K Buy
+500
New +$5.97K 0.01% 465

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

Focused Wealth Management's KERX Position: Q3 2015 in Review

Focused Wealth Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2015, closing a stake of 500 shares — an estimated $5K sold.

Focused Wealth Management first reported a position in KERX in Q4 2013 and held it in 7 quarters. The position peaked at $9K in Q1 2014. 138 funds tracked by Wall St. Rank hold KERX as of Q3 2015.

  • Focused Wealth Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2015 after selling out during the quarter.
  • Focused Wealth Management sold 500 Keryx Biopharmaceuticals Inc shares in Q3 2015, an estimated $5K.
  • Focused Wealth Management first reported a position in Keryx Biopharmaceuticals Inc in Q4 2013 and held it in 7 quarters.
  • Focused Wealth Management's Keryx Biopharmaceuticals Inc position peaked at $9K in Q1 2014.
  • 138 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2015.

Based on Focused Wealth Management's 13F filing for Q3 2015, filed 10 Nov 2015.